Detailed Narrative
Strategic Achievements and Evolution
Novo Nordisk concluded its 2025 strategic aspirations, having more than doubled sales and operating profit since 2019. Obesity care sales surged from DKK 6 billion to DKK 82 billion, and the company expanded its reach to an additional 16 million people with obesity and diabetes treatments. Rare disease is now positioned for growth with late-stage assets like denecimig and etavopivat, and over DKK 300 billion has been returned to shareholders since 2019.
Executive Leadership Transition
The company announced significant changes to its executive management team, with Dave Moore (EVP, U.S. Operations) and Ludovic Helfgott (EVP, Product and Portfolio Strategy) departing. Jamey Millar will join as EVP of U.S. Operations, bringing extensive U.S. market access and commercial strategy experience. Hong Chow will join as EVP of Product and Portfolio Strategy, with deep global leadership in advancing innovation and product strategies.
GLP-1 Market Dynamics and International Operations
The global GLP-1 market grew over 30% in 2025, with Novo Nordisk's total sales increasing 10%. International Operations (IO) sales grew 14%, driven by GLP-1 products in obesity and diabetes, with 44% GLP-1 volume growth. Wegovy launched in 35 new countries in 2025, tripling its reach, and sales reached DKK 28 billion, growing 134%. IO plans further expansion through new online channels and product rollouts like semaglutide 7.2mg for weight loss.
US Operations and Wegovy Pill Launch
U.S. GLP-1 diabetes care sales increased 5%, driven by Ozempic uptake. The Wegovy pill received FDA approval in December 2025 and launched in January 2026, showing encouraging early uptake with around 50,000 prescriptions in its first three weeks, primarily through self-pay. Commercial access for the Wegovy pill is progressing, covering nearly half the lives covered for injectable Wegovy. The combined injectable and pill Wegovy brand is now the leading anti-obesity medication franchise by NBRx in the U.S.
Diabetes Pipeline Advancements
Novo Nordisk reported positive Phase II data for zenagamtide (formerly amycretin) in type 2 diabetes, showing significant A1c and weight reductions for both subcutaneous and oral formulations. The company plans to initiate extensive Phase III programs (AMBITION for T2D, AMAZE for obesity) for zenagamtide in 2026. Additionally, CagriSema demonstrated superior A1c reduction and weight loss in the REIMAGINE 2 Phase III trial for type 2 diabetes.
Obesity and Rare Disease Pipeline
The obesity pipeline includes anticipated results from the REDEFINE 4 trial (Wegovy vs. tirzepatide) in Q1 2026 and the REDEFINE 11 trial (CagriSema weight loss) in early 2027. In rare diseases, the Phase III HIBISCUS readout for etavopivat in sickle cell disease is expected in Q2 2026, and regulatory decisions for denecimig (hemophilia A) are anticipated in H2 2026.
2026 Outlook and Financial Considerations
The company projects adjusted sales and operating profit growth for 2026 to be between -5% and -13% at constant exchange rates, primarily due to pricing headwinds, including lower realized prices in the U.S. and loss of exclusivity in some international markets. This outlook also reflects increased investments in R&D and commercial activities. Capital expenditure is expected to be around DKK 55 billion in 2026, with a projected decline in subsequent years.